- Home
- CLLS vs CTMX Comparison
CLLS vs CTMX Comparison
Compare CLLS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- CTMX
- Stock Information
- Founded
- CLLS 1999
- CTMX 2008
- Country
- CLLS France
- CTMX United States
- Employees
- CLLS N/A
- CTMX N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- CTMX Health Care
- Exchange
- CLLS Nasdaq
- CTMX Nasdaq
- Market Cap
- CLLS 299.0M
- CTMX 349.6M
- IPO Year
- CLLS 2007
- CTMX 2015
- Fundamental
- Price
- CLLS $3.15
- CTMX $2.00
- Analyst Decision
- CLLS Buy
- CTMX Strong Buy
- Analyst Count
- CLLS 1
- CTMX 3
- Target Price
- CLLS $4.00
- CTMX $5.67
- AVG Volume (30 Days)
- CLLS 76.4K
- CTMX 2.4M
- Earning Date
- CLLS 11-03-2025
- CTMX 11-06-2025
- Dividend Yield
- CLLS N/A
- CTMX N/A
- EPS Growth
- CLLS N/A
- CTMX 263.20
- EPS
- CLLS N/A
- CTMX 0.49
- Revenue
- CLLS $63,438,000.00
- CTMX $141,100,000.00
- Revenue This Year
- CLLS N/A
- CTMX N/A
- Revenue Next Year
- CLLS $66.76
- CTMX N/A
- P/E Ratio
- CLLS N/A
- CTMX $3.99
- Revenue Growth
- CLLS 223.09
- CTMX 18.01
- 52 Week Low
- CLLS $1.10
- CTMX $0.40
- 52 Week High
- CLLS $3.35
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- CLLS 54.47
- CTMX 45.62
- Support Level
- CLLS N/A
- CTMX $1.90
- Resistance Level
- CLLS $3.35
- CTMX $2.16
- Average True Range (ATR)
- CLLS 0.15
- CTMX 0.12
- MACD
- CLLS -0.09
- CTMX -0.00
- Stochastic Oscillator
- CLLS 94.03
- CTMX 27.50
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.